Abstract 14770: Reduction With Evolocumab in Complex Coronary Disease Requiring Revascularization: Insights From the FOURIER Trial

医学 传统PCI Evolocumab公司 血运重建 心脏病学 内科学 经皮冠状动脉介入治疗 支架 心肌梗塞 外科 载脂蛋白B 胆固醇 载脂蛋白A1
作者
Kazuma Oyama,Remo H M Furtado,Antônio Fagundes,Thomas A. Zelniker,Minao Tang,Julia Kuder,Sabina A. Murphy,Andrew Hamer,Huei Wang,Anthony Keech,Terje R. Pedersen,Robert P. Giugliano,Marc S. Sabatine,Brian Bergmark
出处
期刊:Circulation [Ovid Technologies (Wolters Kluwer)]
卷期号:142 (Suppl_3) 被引量:3
标识
DOI:10.1161/circ.142.suppl_3.14770
摘要

Introduction: Although PCSK9 inhibitors induce plaque regression and reduce the risk of coronary revascularization overall, their ability to specifically reduce the risk of complex coronary atherosclerosis requiring revascularization has not been explored. Methods: FOURIER was a randomized trial of the PCSK9 inhibitor evolocumab vs. placebo in 27,564 patients with ASCVD on statin therapy (median achieved LDL-C 32 mg/dL vs. 89 mg/dL) followed for a median of 2.2 years. The study database was blindly reviewed to assess characteristics of coronary revascularization procedures. Complex revascularization was the composite of complex PCI (per GLOBAL LEADERS criteria, at least one of: multivessel PCI, 3 or more stents implanted, 3 or more lesions treated, bifurcation PCI with 2 or more stents, or total stent length >60 mm) or CABG. PCI complications included no-reflow, side branch loss, thrombus formation, major dissection, or perforation. The effects of evolocumab on types of revascularization and PCI complications were evaluated using Cox proportional hazards models. Results: 1724 patients underwent revascularization procedures during follow-up. Evolocumab reduced the risk of non-complex PCI by 22% (HR 0.78; 95%CI 0.70-0.88; P<0.001) and the risk of complex revascularization by 29% (HR 0.71; 95%CI 0.61-0.84; P<0.001), including complex PCI by 33% (HR 0.67; 95%CI 0.54-0.84; P<0.001) and CABG by 24% (HR 0.76; 95%CI 0.60-0.96; P=0.019; Figure). The incidence of reported PCI complications tended to be lower with evolocumab (HR 0.74; 95% CI 0.49-1.11). Conclusions: Adding evolocumab to statin therapy reduced the risk of developing complex coronary disease requiring revascularization, including complex PCI and CABG individually. Together with prior coronary imaging findings, these data suggest very aggressive LDL-C lowering to <1 mmol/L has beneficial effects on coronary atherosclerosis burden, anatomical complexity, and the need for intervention.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
古的古的应助小羊要加油采纳,获得10
刚刚
1秒前
小燕子给小燕子的求助进行了留言
2秒前
2秒前
不安寄容完成签到,获得积分10
2秒前
芷毓_Tian发布了新的文献求助10
3秒前
调研昵称发布了新的文献求助20
3秒前
chopin发布了新的文献求助10
3秒前
3秒前
红叶发布了新的文献求助10
4秒前
科目三应助卓大有采纳,获得10
4秒前
cxtmax发布了新的文献求助10
4秒前
完美世界应助111采纳,获得10
4秒前
佟开开完成签到,获得积分10
4秒前
研友_Ze0vBn完成签到,获得积分10
4秒前
4秒前
搜集达人应助淡然向松采纳,获得10
4秒前
小羊完成签到 ,获得积分10
4秒前
隐形曼青应助胡楠采纳,获得10
4秒前
米欧发布了新的文献求助10
5秒前
5秒前
5秒前
华生发布了新的文献求助10
5秒前
Takk发布了新的文献求助10
5秒前
KEYBOY发布了新的文献求助10
5秒前
研友_J8DmjL完成签到 ,获得积分10
6秒前
6秒前
Yukikig发布了新的文献求助10
7秒前
SciGPT应助酸菜鱼火锅采纳,获得10
7秒前
细腻乾完成签到,获得积分10
7秒前
Return应助realize1106采纳,获得10
8秒前
9秒前
涂惠芳发布了新的文献求助10
9秒前
酷波er应助lee采纳,获得10
10秒前
调研昵称发布了新的文献求助10
10秒前
10秒前
10秒前
111完成签到,获得积分20
10秒前
米欧完成签到,获得积分10
11秒前
11秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2500
Востребованный временем 2500
中成药治疗优势病种临床应用指南 2000
Aspects of Babylonian celestial divination : the lunar eclipse tablets of enuma anu enlil 1500
Agaricales of New Zealand 1: Pluteaceae - Entolomataceae 1040
Healthcare Finance: Modern Financial Analysis for Accelerating Biomedical Innovation 1000
Classics in Total Synthesis IV: New Targets, Strategies, Methods 1000
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 纳米技术 内科学 物理 化学工程 计算机科学 复合材料 基因 遗传学 物理化学 催化作用 细胞生物学 免疫学 电极
热门帖子
关注 科研通微信公众号,转发送积分 3447914
求助须知:如何正确求助?哪些是违规求助? 3043709
关于积分的说明 8995581
捐赠科研通 2732147
什么是DOI,文献DOI怎么找? 1498659
科研通“疑难数据库(出版商)”最低求助积分说明 692846
邀请新用户注册赠送积分活动 690661